Series

Responding to COVID-19

The impacts of the 2019 novel coronavirus have quickly spread to affect most industries around the world. While the concern for the health and well-being of individuals is of the utmost priority, our lawyers are closely monitoring the legal implications the outbreak has on your business.

As the world monitors this global health emergency, and begins planning to slowly reopen, we have turned our focus to providing insight and guidance on the topics needed to return to the next normal. Our lawyers are working collaboratively across the globe to help our clients navigate the legal and operational issues arising from the coronavirus pandemic.

Provided below you will find our thought leadership, and timely resources on the subject. If you are looking for something in particular, you can use the filter options below to locate content by topic, region, or type. We also offer a keyword search option to help you find the information you need.

The legal landscape surrounding the effect of the virus is rapidly changing; visit this page regularly for new and updated information or SUBSCRIBE to our All Things COVID-19 email list to receive the latest updates.

Filter
Results

Thought Leadership

20 January 2021

The SEC's Modernized Marketing Rule for Investment Advisers

On 22 December 2020, the U.S. Securities and Exchange Commission (SEC) adopted amendments (the final rule) to Rule 206(4)-1 under the Investment Advisers Act of 1940 (the Advisers Act) to modernize the regulation of investment adviser advertising and solicitation practices.

12 January 2021

Well Done? EEOC's New Proposed Rules Would Limit Employer Wellness Programs to De Minimis Incentives—with Significant Exceptions

On 7 January 2021, the U.S. Equal Employment Opportunity Commission (EEOC) proposed two new rules designed to clarify the scope of incentives that employers may offer employees as part of a wellness program without violating the Americans with Disabilities Act (ADA) or Genetic Information Nondiscrimination Act (GINA).

24 November 2020

COVID-19: Vaccines for Everyone! Wait, Not So Fast. Considerations for Health Care and Other Employers When Evaluating Mandatory COVID-19 Vaccination Programs

Following earlier announcements as to the efficacy of vaccine trials by pharmaceutical companies Pfizer, Inc. (Pfizer) and Moderna, Inc. on November 20, 2020, Pfizer and BioNTech submitted applications for emergency use authorization to the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccinations.

11 January 2021

SBA Publishes PPP 3.0 Regulations and PPP Second Draw Loan Regulations

On Wednesday, 6 January 2021, the U.S. Small Business Administration (SBA) released new guidance on the existing Paycheck Protection Program (PPP) under Sections 1102 and 1106 of the Coronavirus Aid, Relief, and Economic Security Act and on the SBA’s new “Paycheck Protection Program Second Draw Loans."

Series

Responding to COVID-19

Overview

Thought Leadership

Popular On Hub

Email Disclaimer